

### **ATTORNEY DOCKET NO.: 2002834-0043**

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Bannon et al.

Examiner:

Huynh, Phuong N

Serial No.:

09/141,220

Art Unit:

1644

Filing Date:

August 27, 1998

Title:

METHODS AND REAGENTS FOR DECREASING CLINICAL

REACTION TO ALLERGY

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

## TRANSMITTAL LETTER

Enclosed are the following documents:

- 1. Form PTO-1449 (10 pages);
- 2. Supplemental Information Disclosure Statement (5 pages);
- 3. Transmittal Letter (1 page);
- 4. Cited Art (111); and
- 5. Return Postcard.

If any additional fees are required to be paid or if any overpayment has been made, please charge same to Deposit Account No. 03-1721.

Respectfully submitted,

Charles Lyon Ph.D.

Agent for Applicant

Limited Recognition Under 37 CFR 10.9(b)

Choate, Hall & Stewart Exchange Place 53 State Street Boston, MA 02109 (617) 248-5000 Certificate of Mailing

I certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as Pirst Class Mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria NA 22313-1450.

Date

Signature

Sandra Saccocia

Typed or Printed Name of person signing certificate



#### **ATTORNEY DOCKET NO.: 2002834-0043**

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Bannon et al.

Examiner: Huynh, Phuong N

Serial No.:

09/141,220

Art Unit: 1644

Filing Date:

August 27, 1998

Title:

METHODS AND REAGENTS FOR DECREASING CLINICAL

REACTION TO ALLERGY

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

#### INFORMATION DISCLOSURE STATEMENT

Pursuant to the duty of disclosure under 37 CFR §§ 1.56, 1.97 and 1.98, Applicant requests consideration of this Information Disclosure Statement.

### Type of Statement

The present Information Disclosure Statement is:

An *original* Information Disclosure Statement; or

[X] A supplemental Information Disclosure Statement.

Certificate of Mailing

I certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to Commissioner for Patents, P.O. Fox 1450, Alexandria, A 22313-1450.

Date

Signature

S

Sandra Saccocia

Name of Person Signing

### Compliance with 37 CFR § 1.97

The present Information Disclosure Statement is being filed: Pursuant to 37 CFR § 1.97(b); no fee or certification is required: [] [] Within three months of the filing date of a national application other than a continued prosecution application under § 1.53(d); [] Within three months of the date of entry of the national stage as set forth in § 1.491 in an international application; Before the mailing of a first Office action on the merits; or [] [] Before the mailing of a first Office action after the filing of a request for continued examination under § 1.114. Pursuant to 37 CFR § 1.97(c) after the dates listed above but before the mailing [] date of any of a final action under § 1.113, a notice of allowance under § 1.311, or an action that otherwise closes prosecution in the application; Applicant hereby either: [] Certifies that *either*: each item of information contained in the information disclosure [] statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement; or [] That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the

Page 2 of 5 3758648

information disclosure statement was known to any individual

the information disclosure statement; or [] Includes herewith the fee set forth in  $\S 1.17(p)$ , [] Pursuant to 37 CFR § 1.97(d), after the mailing date of any final action under § 1.113, a notice of allowance under § 1.311, or an action that otherwise closes prosecution in the application; Applicant hereby both: Certifies that either: [ ] [] each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement; or [] That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the information disclosure statement; and

Includes herewith the fee set forth in  $\S 1.17(p)$ .

[]

designated in § 1.56(c) more than three months prior to the filing of

Page 3 of 5 3758648

#### Content of the Information Disclosure Statement

Applicant hereby makes of record in the above-identified application the reference(s) listed on the attached form PTO-1449 (modified). The order of presentation of the references should not be construed as an indication of the importance of the references.

Applicant includes copies of references as indicated below:

[X]	A copy of each cited reference not indicated with an asterisk is included;
-----	--

[]	Copies of references indicated with an asterisk on the attached form PTO-1449
	are not included pursuant to 37 CFR § 1.98(d) because they were previously
	provided to the United States Patent Office in an Information Disclosure
	Statement that complies with 37 CFR § 1.98(a)-(c) and was submitted in the
	following patent application that is relied upon in the present case for an earlier
	effective filing date under 35 USC § 120:

Serial Number	Filing Date	Status

[ ] Copies of English translations of one or more non-English references are included.

Applicant hereby makes the following additional information of record in the above-identified application:

Applicant certifies that the Information Disclosure Statement either:

X	Dogg not	contain non	English	languaga	aitationa
$\Lambda$	Does not	Contain non	-611511211	ianguage	Citations.

[ ] Includes one or more translations of a non-English citation; or

[ ] Does contain non-English language citations, of which the following is a concise explanation:

Page 4 of 5 3758648

Remarks

The submission of this Information Disclosure Statement should not be construed as a

representation that a search has been made.

The submission of this Information Disclosure Statement shall not be construed to be an

admission that the information cited in the statement is, or is considered to be, material to patentability as

defined in § 1.56(b).

The submission of this Information Disclosure Statement shall not be construed as a

representation that the information cited in the Statement is, or is considered to be, in fact, prior art as

defined by 35 USC §102.

It is respectfully requested that:

1. The Examiner consider completely the cited information, along with any other

information, in reaching a determination concerning the patentability of the present claims;

2. The enclosed form PTO-1449 be signed by the Examiner to evidence that the cited

patent(s) and publication(s) has (have) been fully considered by the Patent and Trademark Office during

the examination of this application; and

3. The citations for the patent(s) and publication(s) be printed on any patent which issues

from this application.

Notwithstanding any statements by Applicants, the Examiner is urged to form his or her own

conclusions regarding the relevance of the cited reference(s).

Dated: 18/20/04

Respectfully submitted,

Charles E. Lyon, D.Phil.

Agent for Applicant

Limited Recognition Under 37 CFR §10.9(b)

CHOATE, HALL & STEWART

Exchange Place 53 State Street

Boston, Massachusetts 02109

(617) 248-5000

(617) 248-4000

PTO-1449 IN RE U.S. Department of ATTY. DOCKET: APPLICATION NO.: Commerce 2002834-0043 09/141,220 Patent and Trademark Office (REV. 8-83) APPLICANT: Bannon et al. **SUPPLEMENTAL** GROUP: 1644 FILING DATE: INFORMATION DISCLOSURE STATEMENT August 27, 1998 (Use several sheets if necessary) U.S. PATENT DOCUMENTS Examiner's U.S. Patent No. **Applicant** Issue Date Class Subclass **Initials** U.S. PATENT APPLICATIONS Publication Date: Applicant: Group: Art Unit: Examiner's Serial Number: Initials: FOREIGN PATENT DOCUMENTS Examiner's Document No. Country Date Translation Initials Yes No OTHER DOCUMENTS Examiner's Citation (Including Author, Title, Date, Pertinent Pages, Etc.) Initials Amorim, et al., "Suppression of Airway Eosinophilia by Killed Mycobacterium Vaccae-Induced Allergen-Specific Regulatory T-Cells", Nature Medicine, 8(6): 625-629, 2002. Asturias, et al., "Is Tropomyosin an Allergen in Anisakis?", Allergy, 55: 898-890, 2000. Asturias, et al., "Cloning, Isolation, and IgE-Binding Properties of Helixaspersa (Brown Garden Snail) Tropomyosin", Int. Arch Allergy Immunol. 128: 90-96, 2002. Asturias, et al., "Molecular Characterization of American Cockroach Tropomyosin (Periplaneta Americana Allergen 7), a Cross-Reactive Allergen", The Journal of Immunology, **162**: 4342-4348, 1999. Bannon, et al., "Engineering, Characterization and in Vitro Efficacy of the Major Peanut Allergens for Use in Immunotherapy", Int. Arch. Allergy Immunol, 124: 70-72, 2001. Barderas, et al., "Identification and Characterization of Che a 1 Allergen from Chenopodium Album Pollen", Int. Arch. Allergy Immunol. 127: 47-54, 2002.

2				
PTO-1449 (REV. 8-83)	U.S. Department of Commerce Patent and Trademark Office	ATTY. DOCKET: 2002834-0043	IN RE APPLICATION NO.: 09/141,220	
		APPLICANT: Bannon	et al.	
	AL N DISCLOSURE STATEMENT ral sheets if necessary)	FILING DATE: August 27, 1998	GROUP: 1644	
-	Barnes, P.J., "IL-10: A Key Regulator of Allergy, 31: 667-669, 2001.	Allergic Disease", Clinical	and Experimental	
	Bashir, et al., "An Enteric Helminth Infect Antigen", <i>The Journal of Immunology</i> , <b>16</b>	_	lergic Response to Dietary	
	Batanero, et al., "Purification, Amino Acid Ole e 6, a Cysteine-Enriched Allergen from 1997.	<u> </u>	_	
	Beck, et al., "The Polyclonal and Antigen- Injected with Ovalbumin in Alum or Com 123: 1-8, 1989.		-	
	Bissonnette, et al., "Inhibition of Mast Cel Journal of Immunology, <b>145</b> : 3385-3390,	l-Mediated Cytotoxicity by IFN- $\alpha/\beta$ and - $\gamma^1$ ", <i>The</i> 1990.		
	Bock, et al., "The Natural History of Food 1982.	Sensitivity", J.Allergy Cli	n. Immunol. <b>69</b> : 173-177,	
	Bock, et al., "Fatalities Due to Anaphylact 107: 191-193, 2001.	tic Reactions to Foods", J.	Allergy Clin. Immunol.	
-	Brandtzaeg, et al., "Current Understanding Relation to Food Allergy", Ann. N.Y. Acad		noregulation and Its	
	Burks, et al., "Modification of a Major Pea Arch. Allergy Immunol. 118: 313-314, 199		s of IgE Binding", Int.	
	Bush, et al., "Molecular Cloning of a Majo Clin. Immunol. 104: 665-671, 1999.	or Alternaria Alternata Alle	ergen, rAlt a 2", J. Allergy	
	Chang, et al., "Characterization of Enolase Biomed. Sci. 9: 645-655, 2002.	e Allergen from Rhodotoru	la Mucilaginosa", J.	
	Dandeu, et al., "Hydrophobic Interaction (Equ.c1, the Horse Major Allergen", Journ	<b>Q</b> 2 .		
	De Jong, et al., "Identification and Partial Peanut Proteins", Clinical and Experiment	-	-	

OIF	Extra
OCT 2	2 2004 [
448	\$

INFORMATION DISCLOSURE STATEMENT

PTO-1440	RADEMARTOR
(REV. 8-83)	

**SUPPLEMENTAL** 

U.S. Department of Commerce

Patent and Trademark Office

ATTY. DOCKET: 2002834-0043

IN RE APPLICATION NO.:

09/141,220

APPLICANT: Bannon et al.

FILING DATE:

August 27, 1998


GROUP: 1644

(Use	e several sheets if necessary)	August 27, 1996			
-	Diaz-Perales, et al., "Lipid-Transfer Proteins as Potential Plant Panallergens: Cross-Reactivity Among Proteins of Artemisia Pollen, Castanea Nut and Rosaceae Fruits, with Different IgE-Binding Capacities", Clinical and Experimental Allergy, 30: 1403-1410, 2000.				
	Diaz-Perales, et al., "Characterization of Asparagus Allergens: A Relevant Role of Lipid Transfer Proteins", J. Allergy Clin. Immunol. 110: 790-796, 2002.				
	Dorion, et al., "The Production of Interferon-γ in Response to a Major Peanut Allergy, Ara h II, Correlates with Serum Levels of IgE Anti-Ara h II", J. Allergy Clin. Immunol. 93: 93-99, 1994.				
	Durham, et al., "Immunologic Changes Ass Journal of Allergy and Clinical Immunolog	•	unotherapy", The		
	Erb, et al., "Atopic Disorders: A Default Pathway in the Absence of Infection?", <i>Immunol. Today</i> , <b>20</b> : 317-322, 1999.				
	Eriksson, et al., "Cloning and Characterisation of a Group II Allergen from the Dust Mite Tyrophagus Putrescentiae", Eur. J. Biochem. 251: 443-447, 1998.				
	Eriksson, et al., "Cloning of Three New Allergens from the Dust Mite Lepidoglyphus Destructor Using Phage Surface Display Technology", Eur. J. Biochem. 268: 287-294, 2001.				
	Fahlbusch, et al., "Purification and Partial Characterization of the Major Allergen, Cav p 1, from Guinea Pig Cavia Porcellus", <i>Allergy</i> , <b>57</b> : 417-422, 2002.				
	Fiorentino, et al., "Two Types of Mouse T I	Helper Cell", J. Exp. Med.	<b>170</b> : 2081-2095, 1989.		
	Francis, et al., "Induction of IL-10 <sup>+</sup> CD4 <sup>+</sup> CD25 <sup>+</sup> T Cells by Grass Pollen Immunotherapy", <i>J. Allergy Clin. Immunol.</i> 111: 1255-1261, 2003.  Gafvelin, et al., "Cross-Reactivity Studies of a New Group 2 Allergen from the Dust Mite Glycyphagus Domesticus, Gly d 2, and Group 2 Allergens from Dermatophagoides Pteronyssinus, Lepidoglyphus Destructor, and Tyrophagus Putrescentiae with Recombinant Allergens", <i>J. Allergy Clin. Immunol.</i> 107: 511-518, 2001.				
	Giuliani, et al., "Isolation and Purification of a Major Allergen from Parietaria Officinalis Pollen", <i>Allergy</i> , <b>42</b> : 434-440, 1987.				

P	2004			
PTO-1449 (REV. 8-83)	U.S. Department of Commerce Patent and Trademark Office	ATTY. DOCKET: 2002834-0043	IN RE APPLICATION NO.: 09/141,220	
		APPLICANT: Bannon et	· · · · · · · · · · · · · · · · · · ·	
SUPPLEMENT	<b>TAL</b>	FILING DATE:	GROUP: 1644	
	N DISCLOSURE STATEMENT	August 27, 1998		
. (Use seve	eral sheets if necessary)			
	Hansen, et al., "Vaccination with Heat-Kill Allergen-Induced Airway Hyperreactivity a 18", The Journal of Immunology, 164: 223-	and Inflammation: Role of		
	Helm, et al., "Isolation and Characterization Bd90K) Involved in IgE-Mediated Cockroa 172-180, 1996.	· ·		
	Hilger, et al., "Sequence of the Gene Encode 169: 295-296, 1996.	ling cat (Felis Domesticus)	Serum Albumin", Gene,	
	Himly, et al., "Art v 1, the Major Allergen of a Defensin-Like and a Hydroxyproline-Rich	_		
	Hoffman, et al., "Occupational Allergy to Bumblebees: Allergens of Bombus Te Allergy Clin. Immunol. 108: 855-860, 2001.			
	Hoffman, et al., "Allergens in Hymenoptera Venom XXVII: Bumblebee Venom Allergy a Allergens", J. Allergy Clin. Immunol. 97: 812-821, 1996.			
	Hoffman, et al., "Allergens in Bee Venom, III. Identification of Allergen B of Bee Venom as an Acid Phosphatase", J. Allergy Clin. Immunol. 59(5): 364-366, 1977.			
	Horiuti, et al., "Variable Expression of Pathogenesis-Related Protein Allergen in Mountain Cedar (Juniperus Ashei) Pollen", <i>The Journal of Immunology</i> , <b>164</b> : 2188-2192, 2000.			
	Horner, et al., "Identification of the Allergen Psi c 2 from the Basidiomycete Psilocybe Cubensis as a Fungal Cyclophilin". <i>Int. Arch Allergy Immunol.</i> <b>107</b> : 298-300, 1995.			
	Howard, et al., "Regulation of B-Cell Growth and Differentiation by Soluble Factors", Ann. Rev. Immunol. 1: 307-333, 1983.			
	Hsu, et al., "Differential Effects of IL-4 and and Lymphokine-Activated Killer Activity"		· · ·	
	Ichikawa, et al., "Molecular Cloning, Expred d 3), A Cysteine Protease Inhibitor", Clinical			
	Jankulovic, et al "Isolation and Biochemic Allergen", J. Allergy Clin. Immunol. 110: 8		aumatin-Like Kiwi	




				<del>,</del>	
PTO-1449  U.S. Department of Commerce (REV. 8-83)  Patent and Trademark Office		ATTY. DOCKET: 2002834-0043	IN RE APPLICATION NO.: 09/141,220		
			APPLICANT: Bannon et	al.	
SUPPLEMENT	AL		FILING DATE:	GROUP: 1644	
1		SURE STATEMENT	August 27, 1998		
. (Use seve	eral sheets if	necessary)			
		ci, et al., "Transforming Growth sease at an Early Age", <i>J. Allerg</i>	•	ū	
		bbe, et al., "Severe Oral Allergy elated PR-10 Protein in Soybean			
	Kowalski, 485-492, 1	et al., "Mechanisms of Specific 1998.	Immunotherapy of Allergic	Diseases", Allergy, 53:	
		, et al., "Cloning, Expression and rotein from Olive Pollen with A			
			Suppresses Anaphylactic Reactions in a Murine cal Immunology, 101(2): 220-228, 2001.		
	Leung, et a 348: 986-9	al., "Effect of Anti-IgE Therapy 993, 2003.	in Patients with Peanut Alle	ergy", N. Engl. J. Med.	
	1 -	'A Murine Model of Peanut Ana lergen Mimic Human Responses			
		Novel Approaches for the Treat al Immunology, 2: 273-278, 200		rent Opinion in Allergy	
	Li, et al., "Engineered Recombinant Peanut Protein and Heat-Killed Listeria Monocytogenes Coadministration Protects Against Peanut-Induced Anaphylaxis in a Murine Model", <i>The Journal of Immunology</i> , <b>170</b> : 3289-3295, 2003.				
	1 '	Strain-Dependent Induction of Aunization in Mice", <i>The Journal</i>	<b>O</b>	· · · · · · · · · · · · · · · · · · ·	
	1	ro, et al., "cDNA Sequence Ana imental Allergy, <b>24</b> : 765-770, 19	•	rgen, Ole e I", Clinical	
		al., "Characteristics of Hyperser nding Protein (Hal-m-1) in Abalo 548, 1997.	•	-	



	2 2 2004			
PTO-1449 (REV. 8-83)	PADEMARKS	U.S. Department of Commerce Patent and Trademark Office	ATTY. DOCKET: 2002834-0043	IN RE APPLICATION NO.: 09/141,220
,			APPLICANT: Bannon	et al.
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		FILING DATE: August 27, 1998	GROUP: 1644	
•	1	et al., "The Major Allergen of S Chromatography B, <b>756</b> : 85-93,	•	ndicum) is a 2S Albumin",
	Patients w	et al., "Allergenic Cross-Reaction ith Oral Allergy Syndrome: An I 194: 699-707, 1994.		
	Blood Leu	al., "Decreased Release of Hista kocytes After Wasp Venom Imn Production of T Cells", <i>J. Allerg</i>	nunotherapy is Partially D	ue to Induction of IL-10
		al., "Novel Allergen Structures val American Cockroach", <i>The Jo</i> 98.		
		al., "cDNA Cloning and Express us to Paramyosin", <i>Int. Arch. All</i>		<u>-</u>
	Three IgE	al., "Cloning, Characterization a Binding Malassezia Furfur Aller <b>267</b> : 4355-4361, 2000.		
	Romagnan 105: 399-4	i, et al., "The Role of Lymphocy 08, 2000.	tes in Allergic Disease",	J. Allergy Clin. Immunol.
	Rook, et al	., "Give us this Day our Daily G	erms", Immunology Toda	y, <b>19</b> : 113-116, 1998.
	Responses	et al., "Transforming Growth Factor to Cows' Milk Proteins in Infan 104: 1093-1098, 1999.		
	Tropomyo	al., "Cloning and Characterisations and α-Tubulin, from the Mite 130: 258-265, 2003.		
		et al., "Fatal and Near-Fatal Anats", N. Engl. J. Med. 327: 380-38	. •	od in Children and
		Hugh., "Food Allergy. Part 1: Im Allergy and Clinical Immunolog		

(0	IPE			
PTO-1449 (REV. 8-83	U.S. Department of Commerce Patent and Trademark Office	ATTY. DOCKET: 2002834-0043	IN RE APPLICATION NO.: 09/141,220	
11 17.	PADEMARKS	APPLICANT: Bannon e	t al.	
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		FILING DATE: August 27, 1998	GROUP: 1644	
-	Sanchez-Monge, et al., "Isolation and Char Lentils", J. Allergy Clin. Immunol. 106: 95		llergens from Boiled	
	Santos, et al., "Cockroach Allergens and A Major Allergen with Potential Cross-React Clin. Immunol. 104: 329-337, 1999.		<del>-</del> -	
	Saxena, et al., "cDNA Cloning, Expression Ribosomal Protein of Aspergillus Fumigation			
	Schade, et al., "Differences In Antigen-Spe Atopic Dermatitis with and without Cow's Allergy Clin. Immunol. 106: 1155-1162, 20	Milk Allergy: Relevance of		
		from Penicillium Oxalicum and P. Notatum by cid Sequence Analysis", Clinical and Experimental		
	Shen, et al., "Molecular Cloning and Immu Allergen Der f 7", Clinical and Experiment	•		
•	Sicherer, et al., "Prevalence of Peanut and Random Digit Dial Telephone Survey", J. 2	~,	<u> </u>	
•	Smith, et al., "Sequence Polymorphisms and Allergens", Int. Arch. Allergy Immunol. 12	•	Group 2 Dust Mite	
	Smith, et al., "The Molecular Basis of Anti Allergens", J. Allergy Clin Immunol. 107: 9		ween the Group 2 Mite	
	Snapper, et al., "Interferon-γ and B Cell Sti Production", Science, 236: 944-947, 1987.	mulatory Factor-1 Recipro	cally Regulate Ig Isotype	
	Sommergruber, et al., "Molecular Characte Protein from Carrot and its Cross-Reactivit Experimental Allergy, 29: 840-847, 1999.			
	Stanley, et al., "Identification and Mutation Epitopes of the Major Peanut Allergen Ara <b>342</b> (2): 244-253, 1997.	•	1	



(Use sev	veral sheets if necessary)			
	Strobel, et al., "Immune Responses to Dietary Antigens: Oral Tolerance", <i>Immunology Today</i> , <b>19</b> : 173-181, 1998.			
	Strobel, et al., "Oral Tolerance, Systemic Immunoregulation, and Autoimmunity" <i>Ann. N.Y. Acad. Sci.</i> <b>958</b> : 47-58, 2002.			
	Tejera, et al., "Identification, Isolation, and Characterization of Ole e 7, a New Allergen of Olive Tree Pollen", <i>J. Allergy Clin Immunol</i> , <b>104</b> : 797-802, 1999.			
	Tinghino, et al., "Molecular Characterization of a Cross-Reactive Juniperus Oxycedrus Pollen Allergen, Jun o 2: A Novel Calcium-Binding Allergen", <i>J. Allergy Clin Immunol</i> , <b>101</b> : 772-777, 1998.			
	Tsai, et al., "Sequence Analysis and Expression of a cDNA Clone Encoding a 98-kDa Allergen in Dermatophagoides Farinae", <i>Clinical and Experimental Allergy</i> , <b>29</b> : 1606-1613, 1999.			
	Turcanu, et al., "Characterization of Lymphocyte Responses to Peanuts in Normal Children, Peanut-Allergic Children, and Allergic Children who Acquired Tolerance to Peanuts", <i>The Journal of Clinical Investigation</i> , 111(7): 1065-1072, 2003.			
ε	Weiner, et al., "Oral Tolerance: Immune Mechanisms and Treatment of Autoimmune Diseases", <i>Immunology Today</i> , <b>18</b> : 335-343, 1997.			
•	Wopfner, et al., "Molecular and Immunological Characterization of Profilin from Mugwort Pollen", <i>Biol. Chem.</i> <b>383</b> : 1779-1789, 2002.			
	Wu, et al., "Sequencing Analysis of cDNA Clones Encoding the American Cockroach Cr-Allergens", <i>The Journal of Biological Chemistry</i> , <b>271</b> (30): 17937-17943, 1996.			
	Wu, et al., "Cloning of the American Cockroach Cr-PII Allergens: Evidence for the Existent of Cross-Reactive Allergens Between Species", J. Allergy Clin. Immunol, 101: 832-840, 19			
	Wu, et al., "Sequencing and Immunochemical Characterization of the American Cockroach Per a 3 (Cr-PI) Isoallergenic Variants", <i>Molecular Immunology</i> , <b>34</b> (1): 1-8, 1997.			
	Xu, et al., "Cloning, Expression and Immunological Characterization of Ory s 1, the Major Allergen of Rice Pollen", <i>Gene</i> , <b>164</b> : 255-259, 1995.			
Yasueda, et al., "Identification and Cloning of Two Novel Allergens from the Lipop Yeast, Malassezia Furfur", Biochemical and Biophysical Research Communication, 244, 1998.				

OCT 2 2 200

PTO-1449 (REV. 8-83)

**SUPPLEMENTAL** 

U.S. Department of Commerce

Patent and Trademark Office

ATTY. DOCKET: 2002834-0043

IN RE APPLICATION NO.:

09/141,220

APPLICANT: Bannon et al.

FILING DATE:

GROUP: 1644

	N DISCLOSURE STATEMENT ral sheets if necessary)	August 27, 1998	
•	Yeung, et al., "Heat-Killed Listeria Monocytogenes as an Adjuvant Converts Established Murine Th2-Dominated Immune Responses into Th1-Dominated Responses", <i>The Journal of</i>		

Immunology, 161: 4146-4152, 1998. Yi, et al., "Identification of Shared and Unique Immunoglobulin E Epitopes of the Highly Conserved Tropomyosins in Blomia Tropicalis and Dermatophagoides Pteronyssinus", Clin. Exp. Allergy, 32: 1203-1210, 2002.

Yocum, et al., "Epidemiology of Anaphylaxis in Olmsted County: A Population-Based Study", J. Allergy Clin. Immunol. 104: 452-456, 1999.

Yokoyama, et al., "Purification, Identification, and cDNA Cloning of Jun a 2, the Second Major Allergen of Mountain Cedar Pollen", Biochemical and Biophysical Research Communications, 275: 195-202, 2000.

Yu, et al., "Proteomics and Immunological Analysis of a Novel Shrimp Allergen, Pen M 2", The Journal of Immunology, 170: 445-453, 2003.

# **EXAMINER**

### **DATE CONSIDERED**

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

3758659